The latest update is out from Peak Bio (PKBO).
Peak Bio, Inc. has entered into a pivotal Merger Agreement with Akari Therapeutics, leading to Peak Bio becoming a wholly-owned subsidiary of Akari once the merger is complete. Shareholders of Peak Bio are set to receive Akari American Depositary Shares, based on an exchange ratio aligned with the merger terms. This strategic move will blend Peak Bio’s innovative capabilities with Akari’s broader market reach, potentially reshaping the landscape for their stakeholders. The merger is subject to approval by Peak Bio’s stockholders and other customary conditions, promising a significant transformation for both entities upon successful completion.
For a thorough assessment of PKBO stock, go to TipRanks’ Stock Analysis page.
